‘Theranos But Real’: New Blood-Testing Startup Says It Can Predict Health Risks
Helios, a new startup coming out of stealth, says it can provide health insights and disease risks from a single drop of blood.
The Takeaway
- Helios predicts health risks and disease insights from a single blood drop.
- Helios uses proteomics and AI to measure over 1,000 proteins.
- Helios secured $2.3 million in seed funding from Y Combinator and other investors.
With all the renewed interest around the saga of Theranos, two startup founders, Omar Abudayyeh and Jonathan Gootenberg, made the tongue-in-cheek decision to plunk down about $12 for the rights to the URL: theranosbutworks.com.
That URL redirects to the main website for their 16-month-old health- and blood-testing company, Helios, which is coming out of stealth on Wednesday. With just a drop of blood drawn from a small, needle-free device, Abudayyeh, 36, and Gootenberg, 35, say the company can measure over 1,000 proteins within someone’s body that provide insight into their current state of health and predictions about a person’s risk of diseases like heart failure, blood cancers and Alzheimer’s disease over the next 10 years.
Abudayyeh and Gootenberg worked on Helios at Y Combinator earlier this year with a third co-founder, Yousef Badran, a scientist and doctor at Massachusetts General Hospital. When they went to raise money, several prospective investors made the same comment, Abudayyeh recalled: “This sounds like Theranos—but real. We would love to chat.” They ended up with $2.3 million in seed funding from Y Combinator, venture firm Formation and angel investors.
Helios is one of several companies pursuing what’s called proteomics testing, which measures the proteins continually made by cells, tissues and organs. Illumina bought the proteomics company SomaLogic earlier this year, and Thermo Fisher Scientific acquired proteomics company Olink in 2024. Vero Bioscience, spun out of the Stanford lab of scientist Tony Wyss-Coray, is developing a blood test that measures proteins and calculates the biological age of different organs.
Pharma companies utilize proteomics in drug development, and academic and medical centers use it for disease research and diagnoses. Finding ways for consumers to routinely use the information is drawing attention lately, in part because of growing interest in longevity science. The proteins can give people a real-time snapshot of their health, and a way to track if lifestyle changes or other interventions are making a difference. Proteomics can help people spot heart or other health problems that don’t show up on standard blood tests, offering a chance to intervene early.
There has also been a lot of excitement about proteomics after Novo Nordisk gave a presentation in October at the Aging Research & Drug Discovery conference. The company said it drew blood samples from people when they enrolled in clinical trials of its weight-loss drugs Ozempic and Wegovy and then again months later. The company used proteomics analyses to determine patients taking the drugs had slower aging in their organs compared to people who got a placebo.
Proteomics involves a different technology from what Theranos employed. Theranos claimed its machine could run hundreds of standard blood tests using only a small amount of blood.
In the Nathan Fielder movie about the Theranos scandal, “You Can See Everything,” Elizabeth Holmes and her romantic partner Billy Evans are depicted pitching potential investors about a “Theranos 2.0” idea. Evans is the founder of Austin, Texas-based diagnostics startup Haemanthus, which in a New York Times article is described as making a device that can test blood, urine and saliva.
Helios’ device is placed on the upper arm with adhesive, and when you push a button on it, it pricks your arm to retrieve a drop of blood, which is stored on a cartridge. The device is then removed, sealed in a pouch and mailed to Helios’ lab in Boston.
At the lab, the proteins are measured. Helios’ AI models then calculate how organs like the heart, liver, brain and kidneys are functioning and the risk for getting major diseases in the future. The AI agent also makes recommendations about what diet and lifestyle changes, supplements or medications can improve the scores. The algorithm makes its predictions and recommendations based on more than 80,000 scientific papers, genetic studies and clinical trial results.
The test will be available at the start of 2027, initially at longevity clinics and through concierge doctors. Helios plans to charge $250 to $600 per test, depending on the volume the clinics buy. Abudayyeh and Gootenberg said they hope to sell tests directly to consumers through their website by the end of 2027. The direct-to-consumer price has not been set yet.
Abudayyeh and Gootenberg met as undergraduates at the Massachusetts Institute of Technology. They both ended up doing graduate studies in the lab of Feng Zhang, a pioneer of Crispr gene editing in humans. Abudayyeh and Gootenberg co-authored many papers published in prestigious academic journals related to Crispr technology and gene editing. They also co-founded five companies together prior to Helios, including Sherlock Biosciences (a Crispr diagnostics company bought in 2024 by OraSure Technologies) and Tome Biosciences (a gene-editing startup that raised over $200 million before shutting down in 2024 after running out of funds).
Gootenberg, who saw “You Can See Everything” with a group that included Abudayyeh, says the incongruity of the scene where Evans and Holmes are enthusiastically describing to investors their vision for “Theranos 2.0” even as Holmes was due to soon begin serving a prison sentence stuck with him. “Even after what happened, that people would still be receptive speaks a lot to the need for these technologies, the societal need, the investor need. That was pretty striking,” Gootenberg said.
“What Theranos promised and their vision is still super exciting to people and resonates,” said Abudayyeh.
They made a launch video for the Helios website where Abudayyeh acknowledges, “And yes, we know technology has made big promises about a single drop of blood before,” while their scientific and academic credentials flash on the screen as a hopeful reminder that they are different. The video also points out that proteomics technology has been used and validated in labs and companies around the world.
Despite the growing excitement about proteomics tests, Vero’s Wyss-Coray says he too tries to address the inevitable Theranos comparisons that come up. “When I give a talk, I say, ‘This is not Theranos,’” Wyss-Coray says. “It usually gets a laugh.”